GENERAL ORTHOPAEDICS
AAOS: IV tranexamic acid & aminocaproic acid on reducing blood loss in orthopaedic surgery
54 studies (comprising 59 randomized controlled trials with 3402 patients) were included in this meta-analysis comparing the use of either intravenous tranexamic acid (TXA) or intravenous epsilon aminocaproic acid (EACA) to placebo in reducing blood loss in orthopaedic surgery. TXA was observed to significantly reduce intraoperative, postoperative, and total blood loss while reducing transfusion rate compared to placebo. EACA was observed to significantly reduce postoperative and total blood loss, although its effects on intraoperative blood loss and transfusion rate were uncertain. In either case, neither TXA or EACA were associated with an increased risk of thromboembolic events.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
